Facebook Pixel

Experimental Cancer Vaccine Goes Into Clinical Trials

Rate This

First there was surgery, then chemotherapy and radiation. Now researchers may have found another way to fight cancer using the body’s own immune system.

Cornell University researchers have produced the first batch of a cancer vaccine known as NY-ESO-1 recombinant protein that will be used in clinical trials for patients facing either ovarian cancer or melanoma.

While the experimental vaccine is not intended to prevent cancer, it may show to be effective in revving up the body’s immune system to fight an existing tumor.

The protein molecules central to the treatment are found naturally in the human body, but do not normally induce strong immune responses. One goal of the clinical trials, aside from safety, is to maximize the body’s anti-tumor immune response to the NY-ESO-1 protein.

Why proteins are important
Proteomics is the comprehensive study of the proteins within the human body. This includes where the proteins are, how they are expressed, and how they interact with each other. Proteins are important as they affect many bodily functions, including cell growth and maintenance.

Cancer develops when cells grow or divide too rapidly or in an uncontrolled way. Researchers have realized that when certain cancers develop, the levels of some proteins in the blood increase, while others decrease. Therefore, studying proteins should enable researchers to find new ways to detect cancer in its earliest stages.

Two Clinicial Trials
Patients with ovarian cancer in one study conducted at Roswell Park Cancer Institute in Buffalo, NY, and with melanoma in a second study at New York University Medical Center, are receiving the cancer vaccine containing the protein.

The clinical trials will consist of patients receiving the cancer vaccine alone and in combination with other agents, according to a statement from Cornell.

"Making NY-ESO-1 available for these clinical trials allows investigators to test ways to develop effective cancer vaccines," says Carl A. Batt, Cornell Liberty Hyde Bailey Professor and director of the Nanobiotechnology facility.

Add a CommentComments

There are no comments yet. Be the first one and get the conversation started!

Enter the characters shown in the image.
By submitting this form, you agree to EmpowHER's terms of service and privacy policy

We value and respect our HERWriters' experiences, but everyone is different. Many of our writers are speaking from personal experience, and what's worked for them may not work for you. Their articles are not a substitute for medical advice, although we hope you can gain knowledge from their insight.